Biofrontera AG provided earnings guidance for the year 2021. The Group expects revenue from product sales of EUR 25 million to EUR 32 million in fiscal year 2021. EBITDA and EBIT will be introduced as key performance indicators in reporting starting in 2021. Both have become established internationally as target metrics and will replace the previously reported key performance indicator result from operating activities. Based on the above assumptions, the Biofrontera Group expects LBIT between EUR 13 million and EUR 16 million in 2021.